IGF-1 LR3: dosing evidence
> Updated:
Human schedule
Controlled data on this compound are limited. The regimens below were gathered from public sources online (studies and protocols) and are given as a reference, not a usage plan.
IGF-1 LR3 is described in available materials as a once-daily subcutaneous injection. The figures below are a generalized reference drawn from protocols and community reports, not from controlled human clinical trials.
This is a concise reference to regimens described for adults; it is not an individual prescription.
IGF-1 LR3 dosing in the protocols on record mostly falls within 20–100 mcg per day: the breakdown by period follows below.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start | 20 mcg once daily, subcutaneous | Starting dose |
| Typical regimen | 20–50 mcg once daily | Increase if needed |
| Upper range | up to 100 mcg/day; ~4–6 week cycle, then off | Maximum in this schedule |
Background on the molecule, its mechanism and primary sources is covered in the monograph.
Practical dosing and effect details
IGF-1 LR3 is not native human IGF-1: it is an engineered analog with 13 extra amino acids added at the N-terminus and a glutamate-to-arginine substitution at position 3. Francis and colleagues (Journal of Molecular Endocrinology, 1992) showed that this analog binds IGF-binding proteins (IGFBPs) in plasma far more weakly than native IGF-1. Those proteins normally keep most circulating IGF-1 inactive; an analog that mostly escapes that binding stays biologically active at much lower doses, which is why the table above uses microgram, not milligram, figures.
That is also why protocols describe daily small subcutaneous doses rather than infrequent large ones: pushing the dose higher mainly adds load at the injection site rather than changing the mechanism itself. The upper range on this page (a 4 to 6 week cycle, then a break) follows the general caution around continuous, unbroken stimulation of a growth-factor receptor.
This is reference information for planning a research protocol, not a medical recommendation and not instructions for self-administration.
This reference is research-use material. The information is not medical advice and is not intended for diagnosis, treatment or prevention of disease.